S, P., S, W., AM, B., J, O., LS, S., E, B., . . . L, V. (2016). Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: Results from a Phase II, single-arm, multicenter study. Dove Medical Press.
Style de citation Chicago (17e éd.)S, Puhalla, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, et Vahdat L. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.
Style de citation MLA (8e éd.)S, Puhalla, et al. Clinical Effects of Prior Trastuzumab on Combination Eribulin Mesylate Plus Trastuzumab as First-line Treatment for Human Epidermal Growth Factor Receptor 2 Positive Locally Recurrent or Metastatic Breast Cancer: Results from a Phase II, Single-arm, Multicenter Study. Dove Medical Press, 2016.